Transcutaneous antigen delivery system

Lee, Mi Young; Shin, Meong Cheol; Yang, Victor C.

doi:10.5483/bmbrep.2013.46.1.001

Cited by 24 publications

(14 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A major hindrance to topical vaccine delivery is the barrier property of the skin due to the stratum corneum. Only antigens with high lipophilicity and a molecular mass of less than 500 Da can passively traverse the stratum corneum [25]. Hence, it is imperative to employ permeation enhancement approaches for effective topical delivery of vaccines.…”

Section: Topical/transdermal Vaccinationmentioning

confidence: 99%

“…Skin-associated lymphoid tissue (SALT) is involved in the induction of immunity after topical immunization. SALT comprises the Langerhans cells and keratinocytes present in the epidermis, dendritic cells and mast cells present in the dermis, and B and T lymphocytes present in the draining lymph nodes [25]. Langerhans cells are potent APCs which take up antigen, process it, and present it to naive T cells in the draining lymph nodes.…”

Section: Topical/transdermal Vaccinationmentioning

confidence: 99%

See 1 more Smart Citation

Potential of Nanocarriers in Antigen Delivery: The Path to Successful Vaccine Delivery

Patravale¹,

Prabhu²

2014

Nanocarriers

View full text Add to dashboard Cite

Vaccination has indubitably made noteworthy contribution to global health. Recent years have witnessed the employment of subunit antigens rather than inactivated or live attenuated vaccines, owing to the superior safety of the former. The intrinsic weak immunogenicity of subunit antigens makes it imperative to formulate them with an adjuvant. Presently, the armamentarium of approved vaccine adjuvants is very poor. Nanocarriers hold great promise for successful vaccine delivery owing to their versatility, excellent cellular uptake properties, capacity to protect antigen, amenability to targeting, and ability to offer prolonged antigen presentation. All these attributes ultimately endow nanocarriers with immense potential to achieve needle-free vaccine delivery, reduce the number of vaccinations, attain dose sparing of antigen, and lead to stronger immune response generation. Nanocarriers can be explored in manifold ways to accomplish targeted antigen delivery to antigen presenting cells. They can be formulated to contain both antigen and immunostimulant molecules, and they can be engineered from specific materials to achieve antigen presentation through the desired pathway to stimulate a particular arm of the immune response. This review discusses the basics of immune response generation, mechanisms of adjuvanticity by nanocarriers, parameters influencing their adjuvanticity, and finally describes the incredible opportunities offered by a gamut of nanocarriers for vaccine delivery.

show abstract

Section: Topical/transdermal Vaccinationmentioning

confidence: 99%

Section: Topical/transdermal Vaccinationmentioning

confidence: 99%

Potential of Nanocarriers in Antigen Delivery: The Path to Successful Vaccine Delivery

Patravale¹,

Prabhu²

2014

Nanocarriers

View full text Add to dashboard Cite

show abstract

“…Third-generation TCI technologies include the disruption of the stratum corneum in a highly localized manner (9). Materials that self-assemble with nucleic acids into nanocomplexes are widely used in biological and biomedical investigations (10), like in the clinical application of DermaVir and DermaPrep (5).…”

Section: Discussionmentioning

confidence: 99%

In vivo study of targeted nanomedicine delivery into Langerhans cells by multiphoton laser scanning microscopy

Kolonics

Csiszovszki²,

Tőke³

et al. 2014

Experimental Dermatology

View full text Add to dashboard Cite

Epidermal Langerhans cells (LCs) function as professional antigen-presenting cells of the skin. We investigated the LC-targeting properties of a special mannose-moiety-coated pathogen-like synthetic nanomedicine DermaVir (DV), which is capable to express antigens to induce immune responses and kill HIV-infected cells. Our aim was to use multiphoton laser microscopy (MLM) in vivo in order to visualize the uptake of Alexa-labelled DV (AF546-DV) by LCs. Knock-in mice expressing enhanced green fluorescent protein (eGFP) under the control of the langerin gene (CD207) were used to visualize LCs. After 1 h, AF546-DV penetrated the epidermis and entered the eGFP-LCs. The AF546-DV signal was equally distributed inside the LCs. After 9 h, we observed AF546-DV signal accumulation that occurred mainly at the cell body. We demonstrated in live animals that LCs picked up and accumulated the nanoparticles in the cell body.

show abstract

“…The stratum corneum is composed of keratin-rich dead corneocytes embedded in a lipid matrix [33]. In normal conditions, the fluid fraction is minimal and both lipids and keratin are solid, resulting in skin impermeability and elasticity.…”

Section: Barrier Role Of the Stratum Corneummentioning

confidence: 99%

Enhancing tumor specific immune responses by transcutaneous vaccination

Saliba

Heurtault

Bouharoun-Tayoun

et al. 2017

Expert Review of Vaccines

View full text Add to dashboard Cite

Our understanding of the involvement of the immune system in cancer control has increased over recent years. However, the development of cancer vaccines intended to reverse tumor-induced immune tolerance remains slow as most current vaccine candidates exhibit limited clinical efficacy. The skin is particularly rich with multiple subsets of dendritic cells (DCs) that are involved to varying degrees in the induction of robust immune responses. Transcutaneous administration of cancer vaccines may therefore harness the immune potential of these DCs, however, this approach is hampered by the impermeability of the stratum corneum. Innovative vaccine formulations including various nanoparticles, such as liposomes, are therefore needed to properly deliver cancer vaccine components to skin DCs. Areas covered: The recent insights into skin DC subsets and their functional specialization, the potential of nanoparticle-based vaccines in transcutaneous cancer vaccination and, finally, the most relevant clinical trial advances in liposomal and in cutaneous cancer vaccines will be discussed. Expert commentary: To define the optimal conditions for mounting protective skin DC-induced anti-tumor immune responses, investigation of the cellular and molecular interplay that controls tumor progression should be pursued in parallel with clinical development. The resulting knowledge will then be translated into improved cancer vaccines that better target the most appropriate immune players.

show abstract

Transcutaneous antigen delivery system

Cited by 24 publications

References 78 publications

Potential of Nanocarriers in Antigen Delivery: The Path to Successful Vaccine Delivery

Potential of Nanocarriers in Antigen Delivery: The Path to Successful Vaccine Delivery

In vivo study of targeted nanomedicine delivery into Langerhans cells by multiphoton laser scanning microscopy

Enhancing tumor specific immune responses by transcutaneous vaccination

Contact Info

Product

Resources

About